Literature DB >> 28601298

The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw.

Goknur Topaloglu1, Osman Taha Koseoglu2, Cigdem Karaca2, Kemal Kosemehmetoglu3.   

Abstract

OBJECTIVE: The pathogenesis of medication-related osteonecrosis of jaw (MRONJ) is poorly understood. The aim of this prospective study was to determine the effect of chronic dental inflammation on the development of Stage 0 MRONJ based on histopathological findings.
METHODS: The study involved patients with a history of bisphosphonate use and an indication for tooth extraction. Before surgery, C-terminal telopeptide test (CTX) values were collected from all patients. All tooth extractions were performed according to a determined protocol. To detect whether any medication-related osteonecrotic changes were present in the non-exposed bone, biopsy samples were taken from the alveolar bone.
RESULTS: A total of 50 patients were included in the study (39 women and 11 men). The patients were mean age of 57.4 ± 12.1 years. In total, 74 teeth were extracted (29 maxillary and 45 mandibular). Histologic examination of three patients (6%) revealed Stage 0 MRONJ. Postoperatively, the complete mucosal healing success rate was 96%. MRONJ risk was not significantly correlated with low CTX value (p = 0.285).
CONCLUSIONS: Chronic inflammation may contribute to Stage 0 MRONJ; however, its role may not be sufficient alone for its development. Application of a predetermined protocol for dentoalveolar processes will help to prevent MRONJ development.
Copyright © 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-resorptive drug; Bisphosphonate; CTX; MRONJ; Osteonecrosis

Mesh:

Year:  2017        PMID: 28601298     DOI: 10.1016/j.jcms.2017.05.003

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  3 in total

1.  Rescue bisphosphonate treatment of alveolar bone improves extraction socket healing and reduces osteonecrosis in zoledronate-treated mice.

Authors:  Akishige Hokugo; Keiichi Kanayama; Shuting Sun; Kenzo Morinaga; Yujie Sun; QingQing Wu; Hodaka Sasaki; Hiroko Okawa; Courtney Evans; Frank H Ebetino; Mark W Lundy; Keivan Sadrerafi; Charles E McKenna; Ichiro Nishimura
Journal:  Bone       Date:  2019-03-26       Impact factor: 4.398

2.  Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study.

Authors:  Takuma Watanabe; Takeshi Yoshida; Sachi Akizuki; Shigeki Yamanaka; Kazumasa Nakao; Shizuko Fukuhara; Keita Asai; Ryuji Uozumi; Kazuhisa Bessho
Journal:  J Bone Miner Metab       Date:  2022-05-09       Impact factor: 2.626

Review 3.  [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].

Authors:  Matthias Tröltzsch; Markus Tröltzsch; Christoph Pautke; Sven Otto
Journal:  HNO       Date:  2022-01-20       Impact factor: 1.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.